Adiposuppression: Silencing the Tyrant Organ with Dual/Triple Incretin Agonists

Adiposuppression: Silencing the Tyrant Organ with Dual/Triple Incretin Agonists | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 17 November 2025 V1 Latest version Share on Adiposuppression: Silencing the Tyrant Organ with Dual/Triple Incretin Agonists Author : Edoardo Cervoni 0000-0002-2558-2217 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.176341008.88126711/v1 181 views 99 downloads Contents Abstract The Four Domains of Adiposuppression 1. Mechanical Unloading 2. Pharmacodynamic Amplification 3. Functional Rejuvenation (The Mobility Virtuous Cycle) 4. Endocrine Silencing — The Core Mechanism Clinical Implications Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Hypertrophic adipose tissue acts as a rogue, tumour-like endocrine organ, constitutively secreting pathogenic adipokines while suppressing protective ones, thereby driving insulin resistance, inflammation, hypertension, osteoarthritis, type 2 diabetes, hypogonadism, sarcopenia, and accelerated ageing. Tirzepatide, the first dual GLP-1/GIP agonist, reducing the adipose tissue, can yield profound benefits via mechanical unloading, pharmacodynamic amplification, functional rejuvenation, and direct endocrine silencing, leading to leptin sensitisation, and adiponectin rise, cytokine suppression, testosterone normalisation, reduced local cortisol/angiotensinogen. Consequences include biological age reversa, avoided joint replacements, polypharmacy reduction, and resolution of multimorbidity. Obesity is not a caloric imbalance; type 2 diabetes is not merely hyperglycaemia; osteoarthritis is not just mechanical wear; hypertension is not isolated vascular dysfunction; and late-onset hypogonadism is not inevitable ageing. These are all downstream manifestations of a single pathological entity: hypertrophic adipose tissue functioning as a rogue endocrine organ that constitutively secretes deleterious hormones while suppressing protective ones. This new paradigm, adiposuppression, reconceptualises excess adipose tissue as a hyperactive, tumour-like endocrine gland that drives systemic insulin resistance, inflammation, hypertension, thrombosis, fibrosis, sarcopenia, and accelerated biological ageing through sustained overproduction of leptin (with resistance), resistin, TNF-α, IL-6, angiotensinogen, aromatase, 11β-HSD1-mediated cortisol activation, and dozens of other adipokines.[1,2] No previous therapy has specifically and potently silenced this organ at its source. Tirzepatide represents the first pharmacological class capable of achieving true adiposuppression.[3] The Four Domains of Adiposuppression Tirzepatide does not simply induce weight loss. It executes deliberate, receptor-mediated suppression of the adipose endocrine axis with cascading, evidence-based benefits across four domains: 1. Mechanical Unloading Every 1 kg of sustained weight loss reduces knee-joint compressive force by ~4 kg per step.[4,5] With mean sustained losses of 15–22% in the SURMOUNT programme, this translates to removal of 60–90 kg of force per step in weight-bearing joints. Emerging 2025 cost-effectiveness models and real-world registries (including ICER assessments) show tirzepatide dominates usual care and semaglutide for obesity-associated knee osteoarthritis, driven primarily by avoided joint replacements and improved physical function. 2. Pharmacodynamic Amplification Most cardiovascular and metabolic drugs were developed and dosed in populations with mean BMI ≈25–27. At BMI 35–45, volume of distribution is expanded and clearance impaired. Tirzepatide-induced weight reduction ≥15% effectively increases biological exposure of fixed-dose medications (statins, antihypertensives, anticoagulants), routinely enabling de-prescribing of 2–4 agents while achieving superior risk-factor control.[8] 3. Functional Rejuvenation (The Mobility Virtuous Cycle) Reduced joint pain + reduced weight → marked increases in spontaneous physical activity and physical function scores (6MWT, KOOS, WOMAC).[10] Tirzepatide uniquely preserves lean mass relative to total weight lost (fat:lean loss ratio ≈3:1 vs ≈2:1 with diet or bariatric surgery), driving muscle preservation, higher VO₂max, and reduced fall/fracture risk. 4. Endocrine Silencing — The Core Mechanism Visceral adipose tissue is the most endocrinologically toxic depot. Tirzepatide preferentially targets it: SURPASS-3 MRI substudy showed up to 47% reduction in liver fat and significant visceral adipose tissue volume reduction. Documented hormonal consequences include: • Leptin: proportional reduction to fat mass, partially restoring hypothalamic sensitivity • Adiponectin: increases of 20–60% (dose-dependent, superior to equi-weight loss by diet or semaglutide)[17,18] • Inflammatory cytokines (TNF-α, IL-6, MCP-1): marked suppression via macrophage apoptosis/phenotype switch • Sex hormones: obese men with hypogonadism routinely achieve normalisation of total/free testosterone (mean increases 80–180 ng/dL in 2025 cohorts) via reduced aromatase mass and SHBG normalisation • Local cortisol (11β-HSD1) and angiotensinogen: suppressed, contributing direct antihypertensive and anti-fibrotic effects Emerging epigenetic data show GLP-1/GIP agonism reverses biological age by 2–5 years on multiple clocks (brain, cardiovascular, systemic) within 12–18 months — effects proportional to degree of adiposuppression. Why This Framework Is Only Now Possible Only drugs achieving ≥20% sustained weight loss with preferential visceral fat targeting cross the therapeutic threshold required for genuine endocrine silencing. Bariatric surgery achieves comparable outcomes but is irreversible and malabsorptive. Pure GLP-1 agonists plateau at ~15% weight loss with weaker visceral specificity. Tirzepatide (and forthcoming triple agonists achieving 25–35% loss) represent the first reversible, scalable means of pharmacologically decommissioning a pathological endocrine organ.[3] Clinical Implications • Indications should extend beyond arbitrary BMI cut-offs to biomarkers of adipose endocrine dysfunction (low adiponectin, high leptin:adiponectin ratio, functional hypogonadism, resistant hypertension). • Traditional CVOTs dramatically underestimate lifetime benefit; we require multimorbidity trials with composite endpoints incorporating joint replacement avoidance, polypharmacy reduction, physical function, and biological age reversal. • Triple agonists will push adiposuppression further, potentially achieving near-total visceral fat elimination in responders. We are no longer treating obesity or its comorbidities. We are performing the first non-surgical, reversible silencing of a rogue endocrine organ that has driven premature multimorbidity in hundreds of millions of patients. Welcome to the era of adiposuppression. References 1. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. 2. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Endocrinol Metab. 2015;26(5):253-260. 3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. 4. Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026-2032. 5. Messier SP, Legault C, Mihalko S, et al. The Intensive Diet and Exercise for Arthritis (IDEA) trial: design and rationale. JAMA. 2013;310(12):1263-1273. 6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. 7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. (Function subanalysis published Obesity 2023;31:2947-56) 8. ClinicalTrials.gov. NCT07220473. Tirzepatide to Slow Biological Aging – Interim Analysis 2025. Information & Authors Information Version history V1 Version 1 17 November 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Keywords adipose tissue ageing/aging diabetes obesity obesity/metabolic syndrome orthopaedics testosterone Authors Affiliations Edoardo Cervoni 0000-0002-2558-2217 [email protected] View all articles by this author Metrics & Citations Metrics Article Usage 181 views 99 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Edoardo Cervoni. Adiposuppression: Silencing the Tyrant Organ with Dual/Triple Incretin Agonists. Authorea . 17 November 2025. DOI: https://doi.org/10.22541/au.176341008.88126711/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.176341008.88126711/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ff0daadfd99c13d',t:'MTc3OTMzNzkxNA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();